Aberrant Super‐Enhancer Landscape in Human Hepatocellular Carcinoma

Felice Ho‐Ching Tsang, Cheuk‐Ting Law, Tsz‐Ching Chloe Tang, Carol Lai‐Hung Cheng, Don Wai‐Ching Chin, Wing‐Sum Vincy Tam, Lai Wei, Carmen Chak‐Lui Wong, Irene Oi‐Lin Ng, Chun‐Ming Wong – 5 February 2019 – Hepatocellular carcinoma (HCC) cells exploit an aberrant transcriptional program to sustain their infinite growth and progression. Emerging evidence indicates that the continuous and robust transcription of oncogenes in cancer cells is often driven by super‐enhancers (SEs).

Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer InVivo and In Vitro

Anna Saborowski, Katharina Wolff, Steffi Spielberg, Benedikt Beer, Björn Hartleben, Zulrahman Erlangga, Diana Becker, Lukas E. Dow, Silke Marhenke, Norman Woller, Kristian Unger, Peter Schirmacher, Michael P. Manns, Jens U. Marquardt, Arndt Vogel, Michael Saborowski – 5 February 2019 – The rising incidence of cholangiocarcinoma (CCA) coupled with a low 5‐year survival rate that remains below 10% delineates the urgent need for more effective treatment strategies.

Prothrombin Complex Concentrates for Coagulopathy in Liver Disease: Single‐Center, Clinical Experience in 105 Patients

Anja Drebes, Marie de Vos, Sunita Gill, Emma Fosbury, Sue Mallett, Andy Burroughs, Banwari Agarwal, David Patch, Pratima Chowdary – 5 February 2019 – Patients with liver disease frequently develop coagulopathy, and fresh frozen plasma is traditionally used for correction of coagulopathy to manage and prevent bleeding. Prothrombin complex concentrates (PCCs) offer an attractive alternative because they are more readily available and avoid large‐volume transfusion. This retrospective, single‐center study reviewed clinical use of PCC in patients with acute/chronic liver disease.

Exosomal Interferon‐Induced Transmembrane Protein 2 Transmitted to Dendritic Cells Inhibits Interferon Alpha Pathway Activation and Blocks Anti–Hepatitis B Virus Efficacy of Exogenous Interferon Alpha

Ying Shi, Lingyao Du, Duoduo Lv, Hong Li, Jin Shang, Jiajie Lu, Lingyun Zhou, Lang Bai, Hong Tang – 5 February 2019 – The negative regulators in the interferon (IFN) signaling pathway inhibit intrahepatic immune response, resulting in suboptimal therapeutic response to IFNα treatment in chronic hepatitis B (CHB) patients. Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti‐HBV (hepatitis B virus) efficacy of IFNα.

Prominin‐1 Promotes Biliary Fibrosis Associated With Biliary Atresia

Jessica A. Zagory, Michael Fenlon, William Dietz, Menghan Zhao, Marie V. Nguyen, Pavin Trinh, Maeva Adoumie, Alex Park, Jiabo Xu, Elaa Mahdi, Alison Glazier, Nicolas Malkoff, Nirmala Mavila, Kasper S. Wang, in conjunction with the Childhood Liver Disease Research Network – 5 February 2019 – In patients with biliary atresia (BA), the extent of intrahepatic biliary fibrosis negatively correlates with successful surgical bypass of the congenital cholangiopathy as well as subsequent transplant‐free survival.

Outcomes After Listing for Liver Transplant in Patients With Acute‐on‐Chronic Liver Failure: The Multicenter North American Consortium for the Study of End‐Stage Liver Disease Experience

Jacqueline G. O’Leary, Jasmohan S. Bajaj, Puneeta Tandon, Scott W. Biggins, Florence Wong, Patrick S. Kamath, Guadalupe Garcia‐Tsao, Benedict Maliakkal, Jennifer Lai, Michael Fallon, Hugo E. Vargas, Paul Thuluvath, Ram Subramanian, Leroy R. Thacker, K. Rajender Reddy – 5 February 2019 – Acute‐on‐chronic liver failure (ACLF) characterized with ≥2 extrahepatic organ failures in cirrhosis carries a high mortality. Outcomes of patients listed for liver transplantation (LT) after ACLF and after LT are largely unknown.

Subscribe to